Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (91-100 of 224) with videos related to

Pageof 23
Sort By:
Frontiers in Oncology|July 21, 2023
Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an <i>EGFR</i> mutation in tissue: a UK pilot studyHelen Brooks, Ling Li, Alfredo Addeo, et al.
Ecancermedicalscience|July 19, 2017
Brain imaging before primary lung cancer resection: a controversial topicZoe Hudson, Eveline Internullo, Anthony Edey, et al.
Journal of Cancer Policy|June 3, 2023
Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022Timothée Olivier, Claire E P Smith, Alyson Haslam, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2025
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and BackAnnapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
Journal of Clinical Medicine|March 11, 2023
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural MesotheliomaMaxime Borgeaud, Floryane Kim, Alex Friedlaender, et al.
Cancer Treatment Reviews|January 30, 2022
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLCAlex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
International Journal of Molecular Sciences|September 4, 2020
Targeted Therapies in Early Stage NSCLC: Hype or Hope?Alex Friedlaender, Alfredo Addeo, Alessandro Russo, et al.
Clinical Lung Cancer|June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsAlex Friedlaender, Stephen V Liu, Antonio Passaro, et al.
Cancer Investigation|August 19, 2021
Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with ChemotherapyGiuseppe Luigi Banna, Ornella Cantale, Alex Friedlaender, et al.
International Journal of Molecular Sciences|July 29, 2023
Neoadjuvant Immunotherapy: A Promising New Standard of CareEmma Boydell, Jose L Sandoval, Olivier Michielin, et al.
Pageof 23

Showing results (91-100 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|July 21, 2023
Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an <i>EGFR</i> mutation in tissue: a UK pilot studyHelen Brooks, Ling Li, Alfredo Addeo, et al.
Ecancermedicalscience|July 19, 2017
Brain imaging before primary lung cancer resection: a controversial topicZoe Hudson, Eveline Internullo, Anthony Edey, et al.
Journal of Cancer Policy|June 3, 2023
Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022Timothée Olivier, Claire E P Smith, Alyson Haslam, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2025
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and BackAnnapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
Journal of Clinical Medicine|March 11, 2023
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural MesotheliomaMaxime Borgeaud, Floryane Kim, Alex Friedlaender, et al.
Cancer Treatment Reviews|January 30, 2022
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLCAlex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
International Journal of Molecular Sciences|September 4, 2020
Targeted Therapies in Early Stage NSCLC: Hype or Hope?Alex Friedlaender, Alfredo Addeo, Alessandro Russo, et al.
Clinical Lung Cancer|June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsAlex Friedlaender, Stephen V Liu, Antonio Passaro, et al.
Cancer Investigation|August 19, 2021
Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with ChemotherapyGiuseppe Luigi Banna, Ornella Cantale, Alex Friedlaender, et al.
International Journal of Molecular Sciences|July 29, 2023
Neoadjuvant Immunotherapy: A Promising New Standard of CareEmma Boydell, Jose L Sandoval, Olivier Michielin, et al.
Pageof 23